International AIDS Vaccine Initiative Img

International AIDS Vaccine Initiative

IAVI is a global not-for-profit organization working to speed the search for a vaccine to prevent HIV infection and AIDS. Founded in 1996 and operational in 23 countries, IAVI and its network of partners research and develop vaccine candidates. IAVI also advocates for a vaccine to be a global priority and works to assure that a future vaccine will be accessible to all who need it.

Research and Development

IAVI's scientific program researches and develops vaccine candidates by directing and financing partnerships with more than 30 private companies and academic and government agencies worldwide. IAVI manages a portfolio of R&D projects, prioritizing vaccine concepts and candidates given the latest science.

IAVI partnerships have developed five vaccine candidates from the concept stage to human clinical trials, and are now developing other candidates for trials. IAVI has partnerships in 12 countries to conduct trials, and a core laboratory oversees the vaccine testing procedures at each site so that the results on different candidates can be compared.

IAVI is researching new concepts for the design of a vaccine. An IAVI consortium is working to design candidates that elicit broadly neutralizing antibodies, which are believed to be a critical part of a highly effective vaccine, and one of the field's most difficult challenges.

In financial terms, IAVI operates the second largest AIDS vaccine research and development program. To date, IAVI has invested more than US$100 million in vaccine R&D.

Partnering With Developing Countries

IAVI works with scientists in Africa and Asia to study how a vaccine can be effective in populations where most new HIV infections are occurring, and where different subtypes of the virus are circulating. IAVI is also studying how a vaccine can be designed so that it is inexpensive to manufacture and easy to administer.

In Africa and India, IAVI has helped establish capacity for small-scale vaccine trials by building clinics and laboratories and training staff. IAVI is beginning to prepare for possible large-scale trials in these regions.

IAVI's scientific partners agree that if an effective AIDS vaccine is developed with IAVI support, it will be made affordable for developing countries.

Advocacy and Education

IAVI's advocacy program promotes awareness among political and scientific leaders, community groups and others worldwide about the urgent need for a vaccine. In partnership with other organizations, IAVI advocates for public policies to help accelerate vaccine research and development, as well as to speed the approval, manufacture and use of a future vaccine.

In areas where vaccine trials are taking place, IAVI works to educate community members about the research process, and Community Advisory Boards provide input into the setup and conduct of IAVI-sponsored trials.

The IAVI Report newsletter tracks the latest news in the vaccine field, as does IAVI's Web site,, which includes a database of all AIDS vaccine trials and estimates of global expenditures on vaccine R&D. IAVI's Scientific Blueprint series provides comprehensive updates on progress and challenges in the vaccine field.

IAVI's Donors

IAVI's major financial supporters include the Bill & Melinda Gates Foundation; the Rockefeller, Starr and Sloan foundations; the World Bank; BD (Becton, Dickinson & Co.); the European Union; and the governments of Canada, Denmark, Ireland, the Netherlands, Norway, Sweden, the United Kingdom and the United States.

How to Reach International AIDS Vaccine Initiative

110 William Street, Floor 27
New York, NY 10038-3901

Phone: 212.847.1111
Fax: 212.847.1112

Latest by International AIDS Vaccine Initiative

Promo Image

AIDS Researchers Isolate New Potent and Broadly Effective Antibodies Against HIV

New York, N.Y.; La Jolla and South San Francisco, Calif.; Seattle, Wash. -- A team of researchers at and associated with the International AIDS Vaccine Initiative (IAVI), The Scripps Research Institute, the biotechnology company Theraclone Sciences a...

By International AIDS Vaccine Initiative
Promo Image

First Positive Results From Large-Scale HIV Vaccine Trial

Results from an AIDS vaccine trial known as RV144 involving more than 16,000 participants from Thailand show that a prime-boost regimen of two genetically engineered vaccine candidates demonstrated marginal but statistically significant protection ag...

By Regina McEnery and Kristen Jill Kresge for International AIDS Vaccine Initiative
Promo Image

IAVI Statement on Results of Phase III ALVAC-AIDSVAX Trial in Thailand

New York, NY -- The International AIDS Vaccine Initiative (IAVI) greeted with excitement today's announcement by the U.S. Military HIV Research Program and the Thai Ministry of Public Health that, according to an initial analysis, a prime-boost combi...

By International AIDS Vaccine Initiative
Promo Image

Understanding the Conundrum of Immune Activation in HIV/AIDS

In most circumstances, the body's deployment of the immune system (both the innate and adaptive arms) allows it to conquer an invading pathogen (see VAX July 2008 Special Issue, Understanding the Immune System and AIDS Vaccine Strategies). But HIV is...

By Regina McEnery and Kristen Jill Kresge for International AIDS Vaccine Initiative
Promo Image

Understanding Innate Immunity and HIV

Humans are repeatedly exposed to various pathogens, including viruses and bacteria. The body defends itself against these pathogens using a complex network of cells, tissues, and organs, which together form the human immune system (see VAX July 2008 ...

By Regina McEnery for International AIDS Vaccine Initiative
Promo Image

Understanding Cellular Immune Responses

The human immune system uses both innate and adaptive immune responses to combat pathogens such as viruses and bacteria (see VAX March 2004 Primer on Understanding the Immune System, Part II). Innate immune responses are always on standby and can act...

By International AIDS Vaccine Initiative